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Site-directed mutagenesis reveals putative substrate binding
residues in the escherichia coli RND efflux pump AcrB
Abstract
The Escherichia coli multidrug efflux pump protein AcrB has recently been cocrystallized with various
substrates, suggesting that there is a phenylalanine-rich binding site around F178 and F615. We found
that F610A was the point mutation that had the most significant impact on substrate MICs, while other
targeted mutations, including conversion of phenylalanines 136, 178, 615, 617, and 628 to alanine, had
smaller and more variable effects.
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The Escherichia coli multidrug efflux pump protein AcrB has recently been cocrystallized with various
substrates, suggesting that there is a phenylalanine-rich binding site around F178 and F615. We found that
F610A was the point mutation that had the most significant impact on substrate MICs, while other targeted
mutations, including conversion of phenylalanines 136, 178, 615, 617, and 628 to alanine, had smaller and more
variable effects.
The Escherichia coli AcrB multidrug efflux pump is a mem-
ber of the resistance-nodulation-division (RND) family and
recognizes many chemically unrelated compounds, including
various dyes and antibiotics (10, 11). AcrB cooperates with the
membrane fusion protein AcrA and the TolC outer membrane
protein.
While previous crystallographic studies with crystals grown
in trigonal space group R32 described a symmetric AcrB tri-
mer, recent studies of structures derived from monoclinic crys-
tals described an asymmetric trimer in which each protomer
was suggested to correspond to a distinct functional state of a
proposed three-step transport cycle reminiscent of a peristaltic
pump (9, 12, 13). In this model, the protomer in its binding or
tight-state conformation forms a hydrophobic pocket defined
by phenylalanines 136, 178, 610, 615, 617, and 628.
Analysis of doxorubicin- and minocycline-complexed AcrB
crystals suggested that these two compounds interact with dif-
ferent residues of the binding protomer. Minocycline seemed
to interact with F178, N274, and F615, while doxorubicin
seemed to interact with Q176, F615 and F617 (9). Thus, it was
proposed that the extremely broad substrate spectrum of AcrB
could be explained by the flexible interaction of various ligands
mostly with hydrophobic phenylalanines and to a minor degree
with polar residues in the binding pocket.
Support for this model also came from several mutational
studies which found that substrate specificity in RND efflux
pumps is determined by residues in the periplasmic domain
(2–4, 7, 8). A recent study found that the V610F mutation in
the E. coli RND efflux pump YhiV, which is homologous to the
V612F mutation in AcrB, leads to a 16-fold increase in the
linezolid MIC compared to the MIC of the YhiUV-overpro-
ducing wild-type strain (2).
However, no systematic site-directed mutagenesis study of
the phenylalanine residues that form the proposed hydropho-
bic binding pocket in AcrB has been described previously.
In the present study we constructed and tested such phenyl-
alanine mutants to examine the functional role of hydrophobic
residues in the proposed AcrB multidrug binding site. We used
as the parental strain the previously described multidrug-resis-
tant (gyrA marR) acrB-overexpressing E. coli K-12 strain
3-AG100 that was obtained after repeated exposure to a fluo-
roquinolone (5).
For site-directed mutagenesis the phage -based homolo-
gous recombination system (Red/ET counterselection Bac
modification kit; GeneBridges, Heidelberg, Germany) was
used to introduce an rpsL-neo cassette into the acrB gene of
strain 3-AG100 (grown in Luria-Bertani broth) and to subse-
quently replace the cassette with an appropriate oligonucleo-
tide (the sequences of the PCR primers and oligonucleotides
that were obtained from Thermo Electron [Ulm, Germany] are
shown in Table 1). Recombination events were confirmed by
PCR and nucleotide sequencing of the acrB gene using stan-
dard techniques.
To confirm production of the mutant AcrB protein, we per-
formed Western blotting using standard techniques. Most of
the mutants exhibited a strong immunogenic response; the
only exception was an F615A/F617A/F628A triple mutant
which was excluded from further study due to insufficient AcrB
expression (Fig. 1).
We used as a positive control strain F628F, which is a
pseudomutant with MICs and ethidium bromide (EtBr) and
phenylalanine-arginine -naphthylamide (PAN) accumula-
tion properties corresponding to those of wild-type strain
3-AG100. F628A is characterized by a silent mutation from
TTC to TTT (sequence shown in Table 1) that demonstrates
that the site-directed mutagenesis technique has no inherent
effect.
The susceptibilities of the different mutants to various anti-
microbials and dyes and to the putative efflux pump inhibitors
1-naphthylmethylpiperazine (NMP) and PAN were charac-
terized by determining MICs in 96-well microtiter plates as
described previously (1, 2, 6) and are shown in Table 2. EtBr
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FIG. 1. Western blot analysis of mutant AcrB production. Total protein extracts of E. coli 3-AG100 mutants (14 g protein) were separated by NuPAGE
Novex bis-Tris (Invitrogen, California) gel electrophoresis and probed with polyclonal anti-AcrB antibodies. Lanes MW contained molecular weight markers.
TABLE 1. Oligonucleotides and primers used for Red/ET-recombinationa
Oligonucleotide Sequence (5 3 3)
Upper-oligoI (615–628) ...............................................ATCTGACCAAAGAAAAGAACAACGTTGAGTCGGTGTTCGCCGTTAACGGCGGCCTGGTGATGATGG
CGGGATCG
Lower-oligoI (reverse complement orientation) ......TCAACTTTGTTTTCTTCGCCCGGACGATCGGCCCAGTCCTTCAAGGAAACTCAGAAGAACTCGTCAAG
AAGGCG
Upper-oligoII (130–149) .............................................TGGCGATGCCGTTGCTGCCGCAAGAAGTTCAGCAGCAAGGGGTGAGCGTTGGCCTGGTGATGATG
GCGGGATCG
Lower-oligoII (reverse complement orientation) ....ATGGCATCTTTCATATTCGCCGCCACGTAGTCGGAGATATCCTCCTGCGTTCAGAAGAACTCGTCAAG
AAGGCG
Upper-oligoIII (175–194)) ..........................................TGGCGGCGAATATGAAAGATGCCATCAGCCGTACGTCGGGCGTGGGTGATGGCCTGGTGATGATG
GCGGGATCG
Lower-oligoIII (reverse complement orientation)...TTCTGCGCTTTGATGGCGGTAATGACATCAACCGGCGTTAGCTGGAATTTTCAGAAGAACTCGTCAA
GAAGGCG
Repair-oligo 1: rep-acrB-Phe610Ala .........................ACGTTGAGTCGGTGGCAGCCGTTAACGGCTTCGGCTTTGCGGGACGTGGTCAGAATACCGGTATTG
CGTTCGTTTCCTTGAAGGACTGGGCCGATCGTCC
Repair-oligo 2: rep-acrB-Phe615Ala .........................ACGTTGAGTCGGTGTTCGCCGTTAACGGCGCAGGCTTTGCGGGACGTGGTCAGAATACCGGTATTG
CGTTCGTTTCCTTGAAGGACTGGGCCGATCGTCC
Repair-oligo 3: rep-acrB-Phe617Ala .........................ACGTTGAGTCGGTGTTCGCCGTTAACGGCTTCGGCGCAGCGGGACGTGGTCAGAATACCGGTATTG
CGTTCGTTTCCTTGAAGGACTGGGCCGATCGTCC
Repair-oligo 4: rep-acrB-Phe628Ala .........................ACGTTGAGTCGGTGTTCGCCGTTAACGGCTTCGGCTTTGCGGGACGTGGTCAGAATACCGGTATTG
CGGCAGTTTCCTTGAAGGACTGGGCCGATCGTCC
Repair-oligo 5: rep-acrB-Phe628Phe.........................ACGTTGAGTCGGTGTTCGCCGTTAACGGCTTCGGCTTTGCGGGACGTGGTCAGAATACCGGTATTG
CGTTTGTTTCCTTGAAGGACTGGGCCGATCGTCC
Repair-oligo 6: rep-acrB-Del615–617........................GAACAACGTTGAGTCGGTGTTCGCCGTTAACGGCˆˆˆˆˆˆˆˆˆGCGGGACGTGGTCAGAATACCGGTA
TTGCGTTCGTTTCCTTGAAGGACTGGGCCGATCGTCCGGGCG
Repair-oligo 7: rep-acrB-Phe136Ala .........................GCCGCAAGAAGTTCAGCAGCAAGGGGTGAGCGTTGAGAAATCATCCAGCAGCGCACTGATGGTTG
TCGGCGTTATCAACACCGATGGCACCATGACGCAGGAGGATATCTCCGACTACGTGGCGGCGA
Repair-oligo 8: rep-acrB-Phe178Ala .........................AGATGCCATCAGCCGTACGTCGGGCGTGGGTGATGTTCAGTTGGCAGGTTCACAGTACGCGATGCG
TATCTGGATGAACCCGAATGAGCTGAACAAATTCCAGCTAACGCCGGTTGATGTCATTACCG
Forward primer for amplification of repair
oligonucleotides 1–6 ................................................ATCTGACCAAAGAAAAGAACAACGTTGAGTCGGTG
Reverse primer for amplification of repair
oligonucleotides 1–6 ................................................CGCCCGGACGATCGGCCCAGTCCTT
Check-forward primer I ..............................................CCTTCTTGCCAGATGAGGAC
Check-reverse primer I................................................GCAGTACCCAGTTCCACGAT
Check-forward primer II .............................................GTGCAGATCACCCTGACCTT
Check-reverse primer II ..............................................CGTTCTGCGCTTTGATGG
Check-forward primer III ...........................................ACCATGACGCAGGAGGATA
Check-reverse primer III.............................................TAAGCTGTTGGCCTTTCACC
a The upper and lower oligonucleotides include the primer sequences for amplification of the rpsL-neo cassette (indicated by italics). The 5 parts of the oligonucleotides are
homologous to the corresponding acrB regions upstream and downstream (nucleotides 1793 to 1842 and 1885 to 1934 for exchange region I, nucleotides 338 to 387 and 448 to 497
for region II, and nucleotides 473 to 522 and 583 to 632 for region III). The exchanged nucleotide triplets in the repair oligonucleotides are indicated by bold type (e.g., GTT is changed
to TTT at nucleotides 1834 to 1836 in acrB). The underlined sequences in the amplification primers are the priming parts for the repair oligonucleotides, which have to be elongated.
The Check-forward and Check-reverse primers are used to confirm successful exchange of the rpsL-neo cassette and to sequence the modified region of acrB (check PCR product for
acrB region I, nucleotides 1685 to 2030; check PCR product for region II, nucleotides 262 to 634; check PCR product for region III, nucleotides 442 to 691).
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(external concentration, 2.5 M) and PAN (external concen-
tration, 200 M) fluorescence accumulation assays were car-
ried out at least in duplicate for 30 min using our previously
described protocol (2). Both EtBr and PAN are excellent
substrates of AcrAB-TolC and were chosen since they are
structurally diverse; thus, the recognition by the AcrB binding
pocket was assumed to be mediated by different residues. EtBr
is a nonspecific DNA intercalator which, upon binding to its
target structure, causes enhancement of fluorescence, while
the intrinsically low-fluorescence compound PAN is cleaved
by esterases, yielding the highly fluorescent compound -naph-
thylamine as described previously in a study using the related
substrate Ala-Nap (naphthylamide) (6). The results obtained
are shown in Fig. 2a and 2b. We also used an EtBr concentra-
tion of 25 M and a PAN concentration of 20 M and
obtained similar results (data not shown).
The complete disruption of acrB by the rpsL-neo cassette led
to a highly drug-susceptible phenotype and dramatic increases
in EtBr and PAN accumulation. The positive control pseudo-
mutant F628F displayed no changes in the MIC assays or in the
dye accumulation assays. Novobiocin was the only drug whose
MIC was consistently markedly reduced for every single mu-
tant. The F136A, F178A, F615A, F617A, and F628A muta-
tions had very variable effects on substrate MICs. In addition
to the susceptibility of the mutants to novobiocin, the MICs of
oxacillin and the macrolides tested were also reduced in all but
the F617A mutant. F178A markedly increased the susceptibil-
ity to linezolid, and the F628A mutation was found to reduce
the MICs of Hoechst 33342, pyronine Y, and minocycline more
than 4-fold and to increase EtBr and PAN accumulation
2-fold after 30 min.
The crystallographic structure of the asymmetric AcrB tri-
mer suggests that the main interactions between substrates and
protein are due to an ensemble of phenylalanines mediating
hydrophobic interactions, which might explain the extremely
broad substrate specificity (Fig. 3). Surprisingly, although the
AcrB cocrystallization with doxorubicin and minocycline sug-
gested that there is a strong interaction of these substrates with
F178 and F615, the F615A and F178A mutations had no mea-
surable impact on the MICs of these two substrates. Deletion
of amino acids 615 to 617 was associated with minor changes in
the susceptibility to minocycline and some changes in the MICs
of macrolides and oxacillin.
The lack of correlation between the changes in susceptibility
to doxorubicin and minocycline and the model derived from
cocrystallization might have been due to redundancy of phe-
nylalanines in the binding pocket. Mutating or deleting only
one or even two phenylalanines might only lead to a (slight)
reorientation of the substrate and use of other phenylalanines
as hydrophobic interaction partners without generally compro-
mising substrate capture. However, bulkier substrates, like the
macrolides or novobiocin, might be unable to adapt properly in
the altered environment of the pocket and might be affected
more by a single mutation.
To test this hypothesis, we generated the F615A/F617A/
F628A triple phenylalanine mutant; however, since we ob-
tained only a weak Western blot band (Fig. 1), suggesting that
the level of expression of the mutant AcrB protein was low, we
did not include this mutant in further analyses.
The F610A mutant, however, displayed dramatically en-
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hanced susceptibility to almost all AcrB substrates tested (but
not to aminoglycosides and NMP, which are not AcrB sub-
strates), although the absolute changes varied considerably for
different substrates. In contrast, the F610A mutation increased
EtBr accumulation only moderately and did not affect PAN
accumulation. This difference might have been due to the
different time windows between the MIC and fluorescence
experiments. The dramatic impact on substrate MICs indicates
FIG. 2. Increases in EtBr (a) and PAN (b) fluorescence in AcrB phenylalanine mutants compared to pseudomutant AcrB strain F628F. Fluorescence was
recorded for 30 min after addition of 2.5 M EtBr or 200 M PAN. The values are means of at least duplicate experiments. RFU, relative fluorescence units.
8228 NOTES J. BACTERIOL.
 at UNIVERSITATSSPITAL on Novem
ber 27, 2008 
jb.asm.org
D
ow
nloaded from
 
that the F610 residue has a special role in the substrate extru-
sion process, although the exact mechanism remains unclear.
The other targeted mutations, including conversion of phenyl-
alanines 136, 178, 615, 617, and 628 to alanine, generally had
smaller effects on substrate susceptibility and presumably efflux
function and binding, and the effects were variable depending
on the substrate.
This study was supported by BMBF grant 01KI9951.
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FIG. 3. AcrB binding pocket based on the “tight” monomer 2GIF
structure coordinates (12). Phenylalanines are indicated by sticks. The
image was generated using the molecular visualization software PyMol
(http://pymol.sourceforge.net).
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